MDT

86.34

-0.18%↓

115.26

-0.16%↓

VEEV

173.4

-0.26%↓

HQY

83.73

-1.03%↓

PHR.US

8.91

+6.83%↑

MDT

86.34

-0.18%↓

115.26

-0.16%↓

VEEV

173.4

-0.26%↓

HQY

83.73

-1.03%↓

PHR.US

8.91

+6.83%↑

MDT

86.34

-0.18%↓

115.26

-0.16%↓

VEEV

173.4

-0.26%↓

HQY

83.73

-1.03%↓

PHR.US

8.91

+6.83%↑

MDT

86.34

-0.18%↓

115.26

-0.16%↓

VEEV

173.4

-0.26%↓

HQY

83.73

-1.03%↓

PHR.US

8.91

+6.83%↑

MDT

86.34

-0.18%↓

115.26

-0.16%↓

VEEV

173.4

-0.26%↓

HQY

83.73

-1.03%↓

PHR.US

8.91

+6.83%↑

Kodu・Aktsiate loetelu・Lisata Therapeutics

L
Lisata Therapeutics

Avatud

4.99 -0.4

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.99

Max

5.01

Põhinäitajad
By Trading Economics
Sissetulek	1.3M -3M
Müük	100K 100K
Kasumimarginaal	-2,954
Töötajad	21

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2026

Turustatistika
By TradingEconomics
Turukapital	531K 40M
Eelmine avamishind	5.39
Eelmine sulgemishind	4.99

Lisata Therapeutics Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. apr 2026, 04:27 UTC

Uudisväärsed sündmused

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

5. apr 2026, 23:55 UTC

Market Talk

Gold Falls Amid Dollar Strength, Inflation Worries -- Market Talk

5. apr 2026, 23:45 UTC

Market Talk

Nikkei May Decline on Concerns About Energy Costs -- Market Talk

5. apr 2026, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. apr 2026, 23:42 UTC

Market Talk

China's Consumer Inflation Likely Eased in March -- Market Talk

5. apr 2026, 23:38 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Rise Amid Increased Supply Disruption Concerns -- Market Talk

5. apr 2026, 12:57 UTC

Uudisväärsed sündmused

Some Italian Airports Report Jet-Fuel Shortages -- WSJ

3. apr 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. apr 2026, 18:30 UTC

Uudisväärsed sündmused

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3. apr 2026, 18:14 UTC

Market Talk

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3. apr 2026, 17:50 UTC

Market Talk

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3. apr 2026, 17:44 UTC

Omandamised, ülevõtmised, äriostud

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3. apr 2026, 16:50 UTC

Uudisväärsed sündmused

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3. apr 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. apr 2026, 16:12 UTC

Tulu

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3. apr 2026, 15:56 UTC

Market Talk

Uudisväärsed sündmused

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3. apr 2026, 15:56 UTC

Market Talk

Uudisväärsed sündmused

Global Equities Roundup: Market Talk

3. apr 2026, 15:56 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

3. apr 2026, 15:20 UTC

Uudisväärsed sündmused

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3. apr 2026, 15:08 UTC

Omandamised, ülevõtmised, äriostud

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3. apr 2026, 14:11 UTC

Market Talk

Uudisväärsed sündmused

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3. apr 2026, 12:56 UTC

Market Talk

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3. apr 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. apr 2026, 08:01 UTC

Market Talk

Global Equities Roundup: Market Talk

3. apr 2026, 08:01 UTC

Market Talk

Meituan's Profitability Likely to Improve This Year -- Market Talk

3. apr 2026, 07:45 UTC

Market Talk

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3. apr 2026, 06:17 UTC

Market Talk

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3. apr 2026, 06:17 UTC

Market Talk

Global Equities Roundup: Market Talk

3. apr 2026, 04:33 UTC

Market Talk

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3. apr 2026, 04:33 UTC

Market Talk

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Lisata Therapeutics Prognoos

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Lisata Therapeutics aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Maksueelne kasum

Müük

Ärikasum

Ettevõttest Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.